Related Experiment Video

Updated: Aug 21, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Implementing Genetic Cascade Testing for Familial Hypercholesterolemia in Primary Care: Patient and General

Charlene Wright1,2, Jing Pang3, Jennifer A Della-Vedova4

  • 1Centre for Quality and Patient Safety Research, Institute for Health Transformation, School of Nursing and Midwifery, Faculty of Health, Deakin University, Victoria, Australia.

International Journal of Behavioral Medicine
|August 20, 2026
PubMed

Insights

Genetic cascade testing for familial hypercholesterolemia (FH) is underused in primary care. Improving practitioner training and patient education can enhance its implementation for early cardiovascular risk reduction.

Area of Science:

  • Cardiovascular Genetics
  • Primary Care Medicine
  • Public Health

Background:

  • Familial hypercholesterolemia (FH) is a prevalent genetic disorder causing lifelong high cholesterol and early cardiovascular disease.
  • Genetic cascade testing identifies at-risk relatives but is underutilized in primary care settings.
  • Early detection through cascade testing is crucial for cardiovascular risk management.

Purpose of the Study:

  • To explore patient and general practitioner (GP) experiences with FH genetic cascade testing.
  • To identify barriers and facilitators impacting the implementation of FH genetic cascade testing in primary care.
  • To inform strategies for improving the uptake of FH genetic cascade testing.

Main Methods:

  • A mixed-methods approach combining semi-structured interviews with FH patients and parents of children with FH.
  • Open-ended questionnaires administered to general practitioners (GPs) involved in the EDIFICE program.
  • Reflexive thematic analysis of qualitative data to identify key themes.

Main Results:

  • Patients reported varied understanding of FH, diagnostic distress, and challenges navigating care.
  • GPs acknowledged cascade testing's value but noted knowledge gaps and communication issues.
  • Both groups emphasized the need for better educational resources and streamlined referrals.

Conclusions:

  • FH genetic cascade testing in primary care is a vital yet underutilized tool for reducing cardiovascular risk.
  • Enhancing practitioner training, patient education, and healthcare system integration is key to improving implementation.
  • Optimizing FH cascade testing can lead to earlier diagnosis and intervention, improving patient outcomes.
Abstract

Keywords:
Familial hypercholesterolemiaGeneral practitionerGenetic cascade testingImplementationPrimary careQualitative research

More Related Videos

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...